After owning this for years I've grow accustom to the 45 - 38 trading range. As long as they keep paying fat dividends, I wouldn't mind if traders keep this range going for the next 10 years. Just buy and hold dividends add up!
just decided to keep this stock, , they're bringing in the power of artificial intelligence to work in research and developement. that's powerful since human genome complete mapping i think maybe
Any announcement yet for approval of Shingles?
FDA unanimously votes to approve GSK's HIV vaccine today and the stock price is down?
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is -0.1 In other words, the correlation coefficient of the other stocks
GSK, looks to be overvalued at this price check out https://hotstocks123.blogspot.com, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
Moving to October 24 nevermind.
SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
GSK stock is undervalued now. R&D change is positive. I am seeking for stable EPS and revenue in this overvalued market.
Don't buy GSK if you are looking for a stock split or buyout, I guarantee you will be chased out of this stock when traders want to drop it back in the 30's, happens all the time. Buy it if you are looking for a long term nice steady income buy GSK, and Always buy more when it drops below 40. I have been holding GSK since 2003 and couldn't be happier.
I heard today the FDA Ad Comm to review and make recommendations on safety, effectiveness of $GSK Shirgrix vaccine with $Agen adjuvant on Sep 13.
Any opinions on this?
does GSK make polio vaccine,i know Great Britain is donating hundreds of million dollars to complete eradication of polio.very good move, citizens should be proud of their country
The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI
A few weeks ago, when GlaxoSmithKline said it had recruited Pfizer vet Tony Wood to run the platform tech and science group in the pharma R&D operation, the company noted that he was taking the place of John Baldoni, a senior research exec who was la
Fortunately, I did not buy GSK yesterday to get today's dividend of $0.49. I would lose additional $0.3. Not worth it. Short term momentum is negative. I expect the stock will continue down with no upward news.
Some products made tiny sales. Reshape R&D necessary. But it takes long time. Short term, negative. Heading to $38.
...going to realize some return for its shareholders??? WHEN?
GSK has all the right parts and pieces to put it on top, then again - so did Kodak. I'm a long time holder of this disappointing stock and I sure hope changes in management makes some measurable difference to its performance.
Wonder what's today's excuse for the big pre-market drop in GSK's share price?? Perhaps paying huge bonuses to their less-than-able executives and senior management?? When is this poor excuse for a pharmaceutical company
CEO is moving the company away from development of cures or rare exotic diseases for which there is little commercial potential to development of drugs to treat diseases that affect a large population that have far greater market potential. It will take a few years to see the benefits of this change, but is the right decision. Buy GSK as an investment, not a day trade for a quick profit.
Needle-Free Vaccines~~ To Disrupt the Vaccine Industry